Posted by T A P Visit the CNET Brokerage Center for daily reports from the top Wall Street analysts. We are maintaining our A rating on the following company: Genelabs Technologies, Inc. (Nasdaq: GNLB)
Link: Join T A P Free!!
![]()
on 4/4/2001, 7:36 am
04/03/01 08:53 AM
Source: Redchip Review
Morning Call:
Followed by RedChip analyst Wayne Lottinville, CFA
Aslera, the companys lead drug for the treatment of lupus, is well-positioned for FDA approval.
The U.S. licensing of Aslera by Watson Pharmaceuticals, Inc. (NYSE: WPI) is an endorsement of GNLBs lead drug and provides much-needed cash for developing its genetic technology.
The 21-month price target of $8.00 per share is 14x projected 2002 cash flow. This assumes FDA approval of Aslera, but is based on conservative projections of sales and milestone payments.
Message Thread:
![]()
« Back to thread
JOIN T A P FREE TO GET EMAIL UPDATES AND NEW PICKS AS THEY UNFOLD
GO TO TURNAROUNDPICKS MAIN PAGE AND CLICK EMAIL US.